Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5774568

O=C(CCc1cnoc1-c1ccc(C(F)(F)F)cc1)NCc1ccccn1.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
KMT2A Q03164 2/20 0.50
PKM P14618 1/20 0.50
HPGD P15428 2/20 0.49
ALOX15 P16050 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
SORT1 Q99523 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 1/20 0.42
POLB P06746 4/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5770600 0.92 HPGD (0.50) LMNAKMT2APKMHPGDALOX15
Trifluoroacetic Acid SCHEMBL5772978 0.85 GSK3B (0.52) SORT1SMN1; SMN2GAAMAPTALDH1A1
Trifluoroacetic Acid SCHEMBL5774473 0.84 CYP3A4 (0.52) LMNAKMT2ASORT1SMN1; SMN2MAPT
Trifluoroacetic Acid SCHEMBL5775554 0.82 HDAC4 (0.43) KMT2ASMN1; SMN2MAPTALDH1A1TP53
Trifluoroacetic Acid SCHEMBL5775717 0.80 GSK3B (0.44) KMT2ASMN1; SMN2TP53MEN1
Trifluoroacetic Acid SCHEMBL5773866 0.79 ALDH1A1 (0.48) LMNAKMT2ASORT1SMN1; SMN2GAA
Trifluoroacetic Acid SCHEMBL5771101 0.79 TP53 (0.46) LMNAKMT2ASMN1; SMN2NPC1RAB9A
Trifluoroacetic Acid SCHEMBL5776657 0.79 MAPT (0.42) HPGDSMN1; SMN2MAPTTP53
SCHEMBL5773606 0.78 MAPT (0.48) LMNAKMT2ASMN1; SMN2GAAPOLB
SCHEMBL5775471 0.78 HDAC3 (0.46) LMNAKMT2AHPGDSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR LMNA 2770/4885KMT2A 3907/4885PKM 2534/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 LMNA 2605/4885KMT2A 2906/4885PKM 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.